Search
Results: 7682
A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
Simeon Spasov, Luca Passamonti, Andrea Duggento, Pietro Liò, Nicola Toschi, Alzheimer's Disease Neuroimaging Initiative
Feb 07, 2019
Some forms of mild cognitive impairment (MCI) are the clinical precursors of Alzheimer's disease (AD), while other MCI types tend to remain stable over-time and do not progress to AD. To identify and choose effective and...
ADNI Alzheimer's Disease classification Deep learning Early Diagnosis Magnetic Resonance Imaging mild cognitive impairment Neural Networks Aged Aged 80 and over Alzheimer Disease Apolipoprotein E4 Cognitive Dysfunction Deep learning Disease Progression Early Diagnosis Female Humans Magnetic Resonance Imaging Male Models Neurological Neuroimaging Predictive Value of Tests
Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration.
Meng-Shan Tan, Yu-Xiang Yang, Wei Xu, Hui-Fu Wang, Lin Tan, Chuan-Tao Zuo, Qiang Dong, Lan Tan, John Suckling, Jin-Tai Yu, Alzheimer’s Disease Neuroimaging Initiative
Mar 12, 2021
BACKGROUND: Genome-wide association studies have identified more than 30 Alzheimer's disease (AD) risk genes, although the detailed mechanism through which all these genes are associated with AD pathogenesis remains unknown. We...
Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia.
Meng-Shan Tan, Xi Ji, Jie-Qiong Li, Wei Xu, Hui-Fu Wang, Chen-Chen Tan, Qiang Dong, Chuan-Tao Zuo, Lan Tan, John Suckling, Jin-Tai Yu, Alzheimer’s Disease Neuroimaging Initiative
May 22, 2020
BACKGROUND: Models of Alzheimer's disease (AD) pathophysiology posit that amyloidosis [A] precedes and accelerates tau pathology [T] that leads to neurodegeneration [N]. Besides this A-T-N sequence, other biomarker sequences are...
Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease.
Joseph Giorgio, Susan M Landau, William J Jagust, Peter Tino, Zoe Kourtzi, Alzheimer's Disease Neuroimaging Initiative
Jan 28, 2020
Alzheimer's disease brain imaging Cognition Machine Learning mild cognitive impairment Aged Alzheimer Disease Brain Cognitive Dysfunction Disease Progression Female Humans Image Interpretation Computer-Assisted Machine Learning Magnetic Resonance Imaging Male Middle Aged Models Neurological Neuroimaging Prognosis
Clinical and biomarker trajectories in sporadic Alzheimer's disease
Hui-Fu Wang, Xue-Ning Shen, Jie-Qiong Li, John Suckling, Chen-Chen Tan, Yan-Jiang Wang, Lei Feng, Can Zhang, Lan Tan, Qiang Dong, Jacques Touchon, Serge Gauthier, Jin-Tai Yu, Alzheimer's Disease Neuroimaging Initiative
Sep 01, 2020
Introduction: Amyloid beta (Aβ) deposition was identified to precede tau pathology and neurodegeneration in familial Alzheimer's disease (AD). But the divergence between sporadic and familial AD limits the extension of these...
Blood metabolite markers of neocortical amyloid-β burden
N Voyle, M Kim, P Proitsi, NJ Ashton, AL Baird, C Bazenet, A Hye, S Westwood, R Chung, M Ward, GD Rabinovici, S Lovestone, G Breen, C Legido-Quigley, RJB Dobson, SJ Kiddle, Alzheimer's Disease Neuroimaging Initiative
Jun 11, 2018
We believe this is the first study to investigate associations between blood metabolites and neocortical amyloid burden (NAB) in the search for a blood-based biomarker for Alzheimer's disease (AD). Further, we present the first...
Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles
Jin-Tai Yu, Jie-Qiong Li, John Suckling, Lei Feng, An Pan, Yan-Jiang Wang, Bo Song, Shan-Liang Zhu, De-Hu Li, Hui-Fu Wang, Chen-Chen Tan, Qiang Dong, Lan Tan, Vincent Mok, Paul S Aisen, Michael M Weiner, Alzheimer's Disease Neuroimaging Initiative
Aug 21, 2019
INTRODUCTION: We aimed to estimate the frequency of each AT(N) (β-amyloid deposition [A], pathologic tau [T], and neurodegeneration [N]) profile in different clinical diagnosis groups and to describe the longitudinal change in...
Shared genetic contribution to Ischaemic Stroke and Alzheimer's Disease.
Matthew Traylor, Poneh Adib-Samii, Denise Harold, Alzheimer's Disease Neuroimaging Initiative, UK Young Lacunar Stroke DNA resource International Stroke Genetics Consortium (ISGC), Martin Dichgans, Julie Williams, Cathryn M Lewis, Hugh S Markus, METASTROKE, investigators International Genomics of Alzheimer's Project (IGAP)
Feb 23, 2016
Multiple imputation of covariates by fully conditional specification
Jonathan W Bartlett, Shaun R Seaman, Ian R White, James R Carpenter, Alzheimer's Disease Neuroimaging Initiative*
Jun 14, 2018
Missing covariate data commonly occur in epidemiological and clinical research, and are often dealt with using multiple imputation. Imputation of partially observed covariates is complicated if the substantive model is...
Integration of Machine Learning Methods to Dissect Genetically Imputed Transcriptomic Profiles in Alzheimer's Disease.
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.
Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of...
Published by: Molecular neurodegeneration
The Alzheimer's Biomarker Consortium-Down Syndrome
Benjamin L Handen, Ira T Lott, Bradley T Christian, Nicole Schupf, Sid OBryant, Mark Mapstone, Anne M Fagan, Joseph H Lee, Dana Tudorascu, Mei-Cheng Wang, Elizabeth Head, William Klunk, Beau Ances, Florence Lai, Shahid Zaman, Sharon Krinsky-McHale, Adam M Brickman, H Diana Rosas, Annie Cohen, Howard Andrews, Sigan Hartley, Wayne Silverman, Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS)
Aug 28, 2020
INTRODUCTION: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD...
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.
Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of...
Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease
Petroula Proitsi, Michelle K Lupton, Latha Velayudhan, Stephen Newhouse, Isabella Fogh, Magda Tsolaki, Makrina Daniilidou, Megan Pritchard, Iwona Kloszewska, Hilkka Soininen, Patrizia Mecocci, Bruno Vellas, Alzheimer's Disease Neuroimaging Initiative, Julie Williams, GERAD1 Consortium, Robert Stewart, Pak Sham, Simon Lovestone, John F Powell
Nov 08, 2018
BACKGROUND: Although altered lipid metabolism has been extensively implicated in the pathogenesis of Alzheimer disease (AD) through cell biological, epidemiological, and genetic studies, the molecular mechanisms linking...
Modifiable pathways in Alzheimer's disease
Susanna C Larsson, Matthew Traylor, Rainer Malik, Martin Dichgans, Stephen Burgess, Hugh S Markus, on behalf of the International Genomics of Alzheimer’s Project CoSTREAM Consortium
Mar 07, 2018
OBJECTIVE: To determine which potentially modifiable risk factors, including socioeconomic, lifestyle/dietary, cardiometabolic, and inflammatory factors, are associated with Alzheimer's disease. DESIGN: Mendelian randomisation...
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders
Thilo van Eimeren, Angelo Antonini, Daniela Berg, Nico Bohnen, Roberto Ceravolo, Alexander Drzezga, Günter U Höglinger, Makoto Higuchi, Stephane Lehericy, Simon Lewis, Oury Monchi, Peter Nestor, Matej Ondrus, Nicola Pavese, María Cecilia Peralta, Paola Piccini, José Ángel Pineda-Pardo, Irena Rektorová, María Rodríguez-Oroz, Axel Rominger, Klaus Seppi, A Jon Stoessl, Alessandro Tessitore, Stephane Thobois, Valtteri Kaasinen, Gregor Wenning, Hartwig R Siebner, Antonio P Strafella, James B Rowe
May 30, 2019
INTRODUCTION: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early...
Inflammatory biomarkers in Alzheimer's disease plasma.
Angharad R Morgan, Samuel Touchard, Claire Leckey, Caroline O'Hagan, Alejo J Nevado-Holgado, NIMA Consortium, Frederik Barkhof, Lars Bertram, Olivier Blin, Isabelle Bos, Valerija Dobricic, Sebastiaan Engelborghs, Giovanni Frisoni, Lutz Frölich, Silvey Gabel, Peter Johannsen, Petronella Kettunen, Iwona Kłoszewska, Cristina Legido-Quigley, Alberto Lleó, Pablo Martinez-Lage, Patrizia Mecocci, Karen Meersmans, José Luis Molinuevo, Gwendoline Peyratout, Julius Popp, Jill Richardson, Isabel Sala, Philip Scheltens, Johannes Streffer, Hikka Soininen, Mikel Tainta-Cuezva, Charlotte Teunissen, Magda Tsolaki, Rik Vandenberghe, Pieter Jelle Visser, Stephanie Vos, Lars-Olof Wahlund, Anders Wallin, Sarah Westwood, Henrik Zetterberg, Simon Lovestone, B Paul Morgan, Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease
Jul 23, 2019
INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. METHODS: A hypothesis-led...
Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma
Melissa E Petersen, Fan Zhang, Nicole Schupf, Sharon J Krinsky-McHale, James Hall, Mark Mapstone, Amrita Cheema, Wayne Silverman, Ira Lott, Michael S Rafii, Benjamin Handen, William Klunk, Elizabeth Head, Brad Christian, Tatiana Foroud, Florence Lai, H Diana Rosas, Shahid Zaman, Beau M Ances, Mei-Cheng Wang, Benjamin Tycko, Joseph H Lee, Sid O'Bryant, Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS)
May 26, 2021
INTRODUCTION: Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and...
Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Maura Malpetti, Rogier A Kievit, Luca Passamonti, P Simon Jones, Kamen A Tsvetanov, Timothy Rittman, Elijah Mak, Nicolas Nicastro, W Richard Bevan-Jones, Li Su, Young T Hong, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Rowe
May 18, 2020
Tau pathology, neuroinflammation, and neurodegeneration are key aspects of Alzheimer's disease. Understanding whether these features predict cognitive decline, alone or in combination, is crucial to develop new prognostic...
Regional Radiomics Similarity Networks Reveal Distinct Subtypes and Abnormality Patterns in Mild Cognitive Impairment.
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease.
Gina M Peloso, Sven J van der Lee, International Genomics of Alzheimer's Project (IGAP), Anita L DeStefano, Sudha Seshardi
Dec 17, 2018
INTRODUCTION: There is conflicting evidence whether high-density lipoprotein cholesterol (HDL-C) is a risk factor for Alzheimer's disease (AD) and dementia. Genetic variation in the cholesteryl ester transfer protein (CETP)...
Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease.
Alzheimer's disease (AD) is characterised by a dynamic process of neurocognitive changes from normal cognition to mild cognitive impairment (MCI) and progression to dementia. However, not all individuals with MCI develop...
Published by: NeuroImage. Clinical
Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome
Juan Fortea, Eduard Vilaplana, Maria Carmona-Iragui, Bessy Benejam, Laura Videla, Isabel Barroeta, Susana Fernández, Miren Altuna, Jordi Pegueroles, Víctor Montal, Silvia Valldeneu, Sandra Giménez, Sofía González-Ortiz, Laia Muñoz, Teresa Estellés, Ignacio Illán-Gala, Olivia Belbin, Valle Camacho, Liam Reese Wilson, Tiina Annus, Ricardo S Osorio, Sebastián Videla, Sylvain Lehmann, Anthony J Holland, Daniel Alcolea, Jordi Clarimón, Shahid H Zaman, Rafael Blesa, Alberto Lleó
Jul 06, 2020
BACKGROUND: Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with Down syndrome, but the natural history of biomarker...
Adult Alzheimer Disease Amyloid beta-Peptides Amyloidosis Apolipoproteins E Biomarkers Case-Control Studies Cognitive Dysfunction Cross-Sectional Studies Down Syndrome Fluorodeoxyglucose F18 Humans Magnetic Resonance Imaging Middle Aged Neurofilament Proteins Positron-Emission Tomography prevalence Spain United Kingdom tau Proteins
Parp mutations protect from mitochondrial toxicity in Alzheimer's disease.
Alzheimer's disease is the most common age-related neurodegenerative disorder. Familial forms of Alzheimer's disease associated with the accumulation of a toxic form of amyloid-β (Aβ) peptides are linked to mitochondrial...
Published by: Cell Death & Disease
ADDietCoach
The aging population worldwide is expected to increase the prevalence of Alzheimer's disease. As there is no medical curative treatment for this disease to date, alternative treatments have been applied to improve the patient's...
Published by: IGI Global Scientific Publishing
|
|< |
< |
1 |